UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Systematic review: the costs of ulcerative colitis in Western countries

Alimentary pharmacology & therapeutics, 2010-04, Vol.31 (7), p.693-707

2010

Volltextzugriff (PDF)

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

Alimentary pharmacology & therapeutics, 2010-11, Vol.32 (10), p.1228-1239

2010

Volltextzugriff (PDF)

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Alimentary pharmacology & therapeutics, 2010-06, Vol.31 (12), p.1296-1309

2010

Volltextzugriff (PDF)

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

British journal of dermatology (1951), 2012-09, Vol.167 (3), p.658-667

2012

Volltextzugriff (PDF)

Economic burden of comorbidities in patients with psoriasis is substantial

Journal of the European Academy of Dermatology and Venereology, 2011-02, Vol.25 (2), p.157-163

2011

Volltextzugriff (PDF)

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial

British journal of dermatology (1951), 2012-12, Vol.167 (6), p.1374-1381

2012

Volltextzugriff (PDF)

Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study

Journal of the European Academy of Dermatology and Venereology, 2014-06, Vol.28 (6), p.790-798

2014

Volltextzugriff (PDF)

Racial differences in use of biologics for crohn's disease in a medicaid population

Gut, 2011-04, Vol.60 (Suppl 1), p.A138-A138

2011

Volltextzugriff (PDF)

Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (compairs)

Gut, 2011-04, Vol.60 (Suppl 1), p.A136-A136

2011

Volltextzugriff (PDF)

Markov model projection of remission status for early versus delayed step-up adalimumab use in moderate to severe crohn's disease

Gut, 2011-04, Vol.60 (Suppl 1), p.A137-A137

2011

Volltextzugriff (PDF)

Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with crohn's disease: data from extend

Gut, 2011-04, Vol.60 (Suppl 1), p.A136-A137

2011

Volltextzugriff (PDF)

PTU-059Adalimumab Therapy Reduces Hospitalization and Colectomy Rates in Patients with Ulcerative Colitis among Initial Responders

Gut, 2013-06, Vol.62 (Suppl 1), p.A68-A69

2013

Volltextzugriff (PDF)

PTU-059 Adalimumab Therapy Reduces Hospitalization and Colectomy Rates in Patients with Ulcerative Colitis among Initial Responders

Gut, 2013-06, Vol.62 (Suppl 1), p.A68-A69

2013

Volltextzugriff (PDF)

Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial

Journal of Crohn's and colitis, 2013-02, Vol.7 (1), p.34-43

2013

Volltextzugriff (PDF)

PWE-253 Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis

Gut, 2012-07, Vol.61 (Suppl 2), p.A400

2012

Volltextzugriff (PDF)

PWE-253 Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis: Abstract PWE-253 Table 1

Gut, 2012-07, Vol.61 (Suppl 2), p.A400-A401

2012

Volltextzugriff (PDF)

PWE-253Adalimumab improves health-related quality of life for 52weeks in patients with ulcerative colitis

Gut, 2012-07, Vol.61 (Suppl 2), p.A400-A401

2012

Volltextzugriff (PDF)

PWE-260 Optimal C reactive protein cut-off point for predicting hospitalisation in patients with moderately active Crohn's disease

Gut, 2012-07, Vol.61 (Suppl 2), p.A403-A404

2012

Volltextzugriff (PDF)

PWE-260Optimal C reactive protein cut-off point for predicting hospitalisation in patients with moderately active Crohn's disease

Gut, 2012-07, Vol.61 (Suppl 2), p.A403-A404

2012

Volltextzugriff (PDF)

AB1376 Adherence to subcutaneous vs. oral disease-modifying antirheumatic drugs in rheumatoid arthritis

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.716-716

2013

Volltextzugriff (PDF)

AB1395 Switching from adalimumab to other disease-modifying antirheumatic drugs without apparent medical reasons in rheumatoid arthritis: Impact on health care service use

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.717-717

2013

Volltextzugriff (PDF)

PWE-254Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease

Gut, 2012-07, Vol.61 (Suppl 2), p.A401-A401

2012

Volltextzugriff (PDF)

PWE-254 Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease

Gut, 2012-07, Vol.61 (Suppl 2), p.A401-A401

2012

Volltextzugriff (PDF)

OP0002 Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.52-52

2013

Volltextzugriff (PDF)

FRI0145 The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.359-360

2013

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Englisch
(100)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Humans
(32)
Life Sciences & Biomedicine
(32)
Male
(23)
Adalimumab
(22)
Female
(21)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Adult
(19)
Middle Aged
(17)
Treatment Outcome
(17)
Quality Of Life
(16)
Dermatology
(15)
Antibodies, Monoclonal, Humanized
(13)
Psoriasis
(13)
Antibodies, Monoclonal - Therapeutic Use
(11)
Monoclonal Antibodies
(11)
Psoriasis - Drug Therapy
(11)
Severity Of Illness Index
(11)
Crohn's Disease
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Systematic review: the costs of ulcerative colitis in Western countries

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

Economic burden of comorbidities in patients with psoriasis is substantial

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial

Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study

Racial differences in use of biologics for crohn's disease in a medicaid population

Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (compairs)

Markov model projection of remission status for early versus delayed step-up adalimumab use in moderate to severe crohn's disease

Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with crohn's disease: data from extend

PTU-059Adalimumab Therapy Reduces Hospitalization and Colectomy Rates in Patients with Ulcerative Colitis among Initial Responders

PTU-059 Adalimumab Therapy Reduces Hospitalization and Colectomy Rates in Patients with Ulcerative Colitis among Initial Responders

Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial

PWE-253 Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis

PWE-253 Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis: Abstract PWE-253 Table 1

PWE-253Adalimumab improves health-related quality of life for 52weeks in patients with ulcerative colitis

PWE-260 Optimal C reactive protein cut-off point for predicting hospitalisation in patients with moderately active Crohn's disease

PWE-260Optimal C reactive protein cut-off point for predicting hospitalisation in patients with moderately active Crohn's disease

AB1376 Adherence to subcutaneous vs. oral disease-modifying antirheumatic drugs in rheumatoid arthritis

AB1395 Switching from adalimumab to other disease-modifying antirheumatic drugs without apparent medical reasons in rheumatoid arthritis: Impact on health care service use

PWE-254Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease

PWE-254 Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease

OP0002 Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis

FRI0145 The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials

Suchergebnisse filtern